Raymond James Maintains Outperform on First Horizon, Lowers Price Target to $27
Raymond James analyst Daniel Tamayo maintains First Horizon (NYSE:FHN) with a Outperform and lowers the price target from $28 to $27.
Stocks · News reference
This Paymentus Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for MNOV ($6), IBIO ($7), ROIV ($51), and PAY ($42); FHN rated Market Perform at $25.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JP Morgan Maintains Neutral on First Horizon, Lowers Price Target to $26
JP Morgan analyst Anthony Elian maintains First Horizon (NYSE:FHN) with a Neutral and lowers the price target from $27 to $26.
Transcript: First Horizon Q3 2026 Earnings Conference Call
On Thursday, First Horizon (NYSE:FHN) discussed third-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access
First Horizon shares are trading lower after the company reported worse-than-expected Q3 sales results.
8-K filing — iBio, Inc. (IBIO)
Filed: 2026-10-13 AccNo: 0001420720-26-000030 Size: 163 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
iBio Highlights Preclinical Body-Composition Data From Obese NHP Study Evaluating IBIO-610, Activin E Antibody Candidate, Alone And In Combination With Semaglutide, GLP-1 Receptor Agonist Used To Treat Obesity
In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneiBio expects to start first-in-human trials of IBIO-610 in